ESI-HRMS spectra for Kylo-0603. by Xueqin lu (22250795)

Subjects: “…attenuates fibrosis progression…”

Effects of Kylo-0603 on the expression of related genes of the MASH mouse models. by Xueqin lu (22250795)

Subjects: “…attenuates fibrosis progression…”

General procedure for the synthesis of B. by Xueqin lu (22250795)

Subjects: “…attenuates fibrosis progression…”

Effects of Kylo-0603 on body weight, organ weight, and body fat content. by Xueqin lu (22250795)

Subjects: “…attenuates fibrosis progression…”

The body weight and cholesterol levels of the mice were recorded before the administration of the drug. by Xueqin lu (22250795)

Subjects: “…attenuates fibrosis progression…”

The trends of cholesterol metabolism-related gene expression in liver tissue. by Xueqin lu (22250795)

Subjects: “…attenuates fibrosis progression…”

Kylo-0603’s EC50 & tissue levels. by Xueqin lu (22250795)

Subjects: “…attenuates fibrosis progression…”

DIO Mice Liver Staining. by Xueqin lu (22250795)

Subjects: “…attenuates fibrosis progression…”

The Fibrosis scoring by Sirius Red staining and SHG/TPEF. by Xueqin lu (22250795)

Subjects: “…attenuates fibrosis progression…”

Pharmacological efficacy of Kylo-0603 in MASH mouse models (F2 ~ 3). by Xueqin lu (22250795)

Subjects: “…attenuates fibrosis progression…”

After 8 weeks of treatment, body fat analysis and bone mineral density testing of mice in each group. by Xueqin lu (22250795)

Subjects: “…attenuates fibrosis progression…”

Plasma cholesterol and LDL-C levels. by Xueqin lu (22250795)

Subjects: “…attenuates fibrosis progression…”

The Chol and TG content in liver homogenates of the mice in each group after 2 and 10 weeks of drug intervention. by Xueqin lu (22250795)

Subjects: “…attenuates fibrosis progression…”

Hematoxylin and eosin (H&E) staining, Sirius Red staining, and Oil Red staining of liver tissues from mice in each group after 8 weeks of treatment with either vehicle or Kylo-0603... by Xueqin lu (22250795)

Subjects: “…attenuates fibrosis progression…”

Effect of Kylo-0603 drug on the reversal of steatosis and inhibition of fibrotic process in liver tissues of the MASH mouse models (F2 ~ 3), analyzed by SHG/TPEF microscopy combine... by Xueqin lu (22250795)

Subjects: “…attenuates fibrosis progression…”

Error analysis. (a) Location-1 loading. (b) Location-2 loading. by Changxi Shan (22493205)

Subjects:

General procedure for the synthesis of Kylo-0603. by Xueqin lu (22250795)

Subjects: “…attenuates fibrosis progression…”

Chromatograms proved the selectivity of the proposed method. Red line: tissue spiked at the LOQ level; green line: blank tissue. Panel A: SIM and SIMA; panel B: LOV and LOVA. by Ewa Paszkowska (21246702)

Subjects:

Presentation 1_Decreased brain-derived neurotrophic factor expression in chronic kidney disease: integrated clinical and experimental evidence.pptx by Juan Chen (61123)

“…In 14-day UUO mice, renal immunohistochemistry (IHC) showed significantly reduced BDNF expression (P < 0.001), which was further validated by Western blot analysis demonstrating a progressive decline in BDNF protein levels from day 14 to day 21 post-obstruction. …”

Forest plot showing the ratio of odds of acute side effects: nausea (a) and vomiting (b) (=events) among pediatric patients with brain tumors treated with PT or XRT. by Renáta Kiss-Miki (20760127)

Subjects: